scholarly journals piggyBac-Based Non-Viral In Vivo Gene Delivery Useful for Production of Genetically Modified Animals and Organs

Pharmaceutics ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 277 ◽  
Author(s):  
Masahiro Sato ◽  
Emi Inada ◽  
Issei Saitoh ◽  
Satoshi Watanabe ◽  
Shingo Nakamura

In vivo gene delivery involves direct injection of nucleic acids (NAs) into tissues, organs, or tail-veins. It has been recognized as a useful tool for evaluating the function of a gene of interest (GOI), creating models for human disease and basic research targeting gene therapy. Cargo frequently used for gene delivery are largely divided into viral and non-viral vectors. Viral vectors have strong infectious activity and do not require the use of instruments or reagents helpful for gene delivery but bear immunological and tumorigenic problems. In contrast, non-viral vectors strictly require instruments (i.e., electroporator) or reagents (i.e., liposomes) for enhanced uptake of NAs by cells and are often accompanied by weak transfection activity, with less immunological and tumorigenic problems. Chromosomal integration of GOI-bearing transgenes would be ideal for achieving long-term expression of GOI. piggyBac (PB), one of three transposons (PB, Sleeping Beauty (SB), and Tol2) found thus far, has been used for efficient transfection of GOI in various mammalian cells in vitro and in vivo. In this review, we outline recent achievements of PB-based production of genetically modified animals and organs and will provide some experimental concepts using this system.

FEBS Letters ◽  
2001 ◽  
Vol 504 (3) ◽  
pp. 99-103 ◽  
Author(s):  
Kenneth Lundstrom ◽  
Christophe Schweitzer ◽  
Daniel Rotmann ◽  
Danielle Hermann ◽  
Edith M. Schneider ◽  
...  

2016 ◽  
Vol 27 (3) ◽  
pp. 549-561 ◽  
Author(s):  
M. Dolores Giron-Gonzalez ◽  
Rafael Salto-Gonzalez ◽  
F. Javier Lopez-Jaramillo ◽  
Alfonso Salinas-Castillo ◽  
Ana Belen Jodar-Reyes ◽  
...  

2016 ◽  
Vol 55 (39) ◽  
pp. 12013-12017 ◽  
Author(s):  
Yilong Cheng ◽  
Roma C. Yumul ◽  
Suzie H. Pun

Biomaterials ◽  
2006 ◽  
Vol 27 (32) ◽  
pp. 5596-5602 ◽  
Author(s):  
Amit Saxena ◽  
Subho Mozumdar ◽  
Atul Kumar Johri

2017 ◽  
Vol 5 (24) ◽  
pp. 4732-4744 ◽  
Author(s):  
A. Venault ◽  
Y.-C. Huang ◽  
J. W. Lo ◽  
C.-J. Chou ◽  
A. Chinnathambi ◽  
...  

Although PEGylated polyplexes for gene delivery are widespread, there is a need for an in-depth investigation of the role of the PEGylation degree on the delivery efficiency of the systems.


PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e47159 ◽  
Author(s):  
Hong-Sheng Wang ◽  
Zhuo-Jia Chen ◽  
Ge Zhang ◽  
Xue-Ling Ou ◽  
Xiang-Ling Yang ◽  
...  

1998 ◽  
Vol 65 (12) ◽  
pp. S79
Author(s):  
J G??mez-Navarro ◽  
J Contreras ◽  
G Bilbao ◽  
C Asiedu ◽  
Z Huang ◽  
...  

Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 930 ◽  
Author(s):  
Henning Madry ◽  
Jagadeesh Kumar Venkatesan ◽  
Natalia Carballo-Pedrares ◽  
Ana Rey-Rico ◽  
Magali Cucchiarini

Osteochondral defects involve both the articular cartilage and the underlying subchondral bone. If left untreated, they may lead to osteoarthritis. Advanced biomaterial-guided delivery of gene vectors has recently emerged as an attractive therapeutic concept for osteochondral repair. The goal of this review is to provide an overview of the variety of biomaterials employed as nonviral or viral gene carriers for osteochondral repair approaches both in vitro and in vivo, including hydrogels, solid scaffolds, and hybrid materials. The data show that a site-specific delivery of therapeutic gene vectors in the context of acellular or cellular strategies allows for a spatial and temporal control of osteochondral neotissue composition in vitro. In vivo, implantation of acellular hydrogels loaded with nonviral or viral vectors has been reported to significantly improve osteochondral repair in translational defect models. These advances support the concept of scaffold-mediated gene delivery for osteochondral repair.


Sign in / Sign up

Export Citation Format

Share Document